ReviewWomen's health (London, England)2016

Benefits/risks of sodium-glucose co-transporter 2 inhibitor canagliflozin in women for the treatment of Type 2 diabetes.

Pamela KushnerPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.